memantine and Sleep Wake Disorders studies

Sleep Wake Disorders: Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.

Research Excerpts

Excerpt	Relevance	Reference
"Memantine was well tolerated in PD; however, specific measures of sleepiness, fatigue, depression, and attention did not significantly improve."	5.15	Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. ( Davidson, A; Lai, D; Ondo, WG; Shinawi, L, 2011)
"Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)."	2.53	Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016)
"Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder."	2.44	Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008)
" Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised."	2.42	The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. ( Herrmann, N; Lanctôt, KL; Thompson, S, 2004)

Research

Studies (6)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Analyses Will be Computed for the Categorical Dependent Variable (DV): Global Tremor Assessment by Examiner

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Szeto, JY	1
Lewis, SJ	1
Merims, D	1
Freedman, M	1
Brodaty, H	1
Ishida, T	1
Kamei, C	1
Ondo, WG	1
Shinawi, L	1
Davidson, A	1
Lai, D	1
Thompson, S	1
Lanctôt, KL	1
Herrmann, N	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A 16 Week, Investigator-initiated, Single-center, Double Blind, Randomized, Placebo-controlled Trial of Namenda® (Memantine Hcl) for Non-motor Symptoms in Parkinson's Disease[NCT00646204]	Phase 4	40 participants (Actual)	Interventional	2006-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change from baseline to end of study in the following assessment: global tremor assessment by examiner. The maximum total score is 48 and would indicate a high prevalence of tremor. The minimum total score is 0 and would indicate no tremor. (NCT00646204)
Timeframe: Baseline and 16 weeks

Unified Parkinson Disease Rating Scale (UPDRS).

Intervention	scores on a scale (Mean)
	Baseline	16 Weeks
Memantine-1	2.8	2.8
Placebo-2	2.8	2.8

Assess the overall change from baseline in ON state motor United Parkinson Disease Rating scale (UPDRS) scores as assessed in the scale. The minimum score is 0 and the maximum score 199. The maximum score of 199 means the worst possible disability from Parkinson's Disease. (NCT00646204)
Timeframe: Baseline and 16 weeks

Article	Year
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Current neuropharmacology, 2016, Volume: 14, Issue:4 Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th	2016
Cognitive and behavioural impairment in Parkinson's disease. International review of psychiatry (Abingdon, England), 2008, Volume: 20, Issue:4 Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo	2008
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert opinion on drug safety, 2004, Volume: 3, Issue:5 Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseas	2004

Article	Year
Three steps forward, two steps back in helping people with dementia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009, Volume: 17, Issue:2 Topics: Dementia; Humans; Memantine; Self-Help Devices; Sleep Wake Disorders	2009
Characteristic effects of anti-dementia drugs on rat sleep patterns. Journal of pharmacological sciences, 2009, Volume: 109, Issue:3 Topics: Animals; Dementia; Donepezil; Dose-Response Relationship, Drug; Electroencephalography; Electromyogr	2009

memantine and Sleep Wake Disorders